Biochemical Pharmacology of Blood and Bloodforming Organs (Handbook of Experimental Pharmacology) (Reprint)

個数:
  • ポイントキャンペーン

Biochemical Pharmacology of Blood and Bloodforming Organs (Handbook of Experimental Pharmacology) (Reprint)

  • ウェブストア価格 ¥23,849(本体¥21,681)
  • Springer Verlag(2012/07発売)
  • 外貨定価 US$ 109.99
  • 【ウェブストア限定】洋書・洋古書ポイント5倍対象商品(~2/28)
  • ポイント 1,080pt
  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 603 p.
  • 言語 ENG
  • 商品コード 9783642758676
  • DDC分類 615

Full Description

A large number of chemical agents are known which affect blood and blood-forming organs. The purpose of this volume is to review the sig- nificant advances made over the past several years regarding such chemical agents. The purification, biological action, and therapeutic implications of several widely used hematopoietic growth factors such as interleukin 3 (IL-3 or multi-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), colony stimu- lating factor (CSF-I or M-CSF), thrombopoietin, and erythropoietin are included in this volume. These factors are important in regulating several hematopoietic cell lines such as neutrophils, monocytes, eosinophils, macrophages, megakaryocytes, platelets, and erythrocytes. People are exposed daily to numerous toxic chemical substances present in our environment which produce a suppression of erythropoiesis, myelo- poiesis, lymphocytopoiesis, and megakaryocytopoiesis.
Attempts have been made in this volume to assess the therapeutic role of some of the hematopoietic factors such as erythropoietin in the anemia of end stage renal disease, as well as colony stimulating factors in other hematopoietic abnormalities. In addition, some of the chemical factors in our environment which suppress major hematopoietic lineages stimulated by erythropoietin, macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin I-alpha, interleukin I-beta, and interleukins 2, 3, 4, 5, 6, 7, and 9 are also included. An updating of the mechanism of action of each of these factors on the major hematopoietic lineages is covered.

Contents

1 Introduction.- 2 Fundamental Control of Hematopoiesis.- A. Introduction.- B. Hierarchical Organization of Hematopoietic Cells.- C. Assay and Characterization of In Vitro Clonogenic Cells.- D. Use of In Vitro Clonogenic Cell Assays.- E. Newer Assays for More Primitive Cells.- F. Regulatory Mechanisms.- G. Future Outlook.- References.- 3 Kidney Regulation of Erythropoietin Production.- A. Introduction.- B. Model for the Control of Erythropoietin Production.- C. Hypoxia and Erythropoietin Production.- D. Adenosine and Erythropoietin Production.- References.- 4 The Mechanism of Action of Erythropoietin: Erythroid Cell Response.- A. Introduction.- B. Model Systems for Studying the Interaction of Erythropoietin with Erythroid Progenitor Cells.- C. Interaction of Other Growth and Development Factors with Erythroid Progenitor Cells.- D. The Erythroid Differentiation Program.- E. Signal Transduction in Erythroid Progenitor Cells.- F. Erythropoietin as a Competence or Progression Factor.- G. Conclusion.- References.- 5 The Arachidonic Acid Cascade and Erythropoiesis.- A. Introduction.- B. Evidence for the Roles of Arachidonic Acid Metabolism in Erythropoiesis.- C. Future Directions for Research.- References.- 6 Iron Deficiency and Megaloblastic Anemias.- A. Iron-Deficiency Anemia.- B. Megaloblastic Anemias.- References.- 7 Erythropoietin in the Anemia of End-Stage Renal Disease.- A. Assay of Erythropoietin.- B. Pathogenesis of the Anemia of Chronic Renal Failure.- C. Kidney Production of Erythropoietin.- D. Erythropoietin in Therapy of Renal Anemia.- E. Conclusions.- References.- 8 Humoral Control of Thrombocytopoiesis.- A. Introduction.- B. Model for Megakaryocytopoiesis.- C. Controlling Factors.- D. Other Factors Affecting Thrombocytopoiesis.- E. Clinical Aspects of Thrombopoietin.- F. Future of Thrombopoietin.- References.- 9 Arachidonic Acid Metabolism Platelets and Thromboembolic Disease.- A. Arachidonic Acid Metabolism.- B. Thromboembolic Disease.- C. Concluding Comments.- References.- 10 Chemical Agents That Inhibit Platelet Aggregation.- A. Introduction.- B. Platelet Physiology.- C. Platelet Structure.- D. Platelet Involvement in Thrombosis.- E. Platelet Responses.- F. Inhibition of Platelet Aggregation.- G. Conclusions.- References.- 11 Anticoagulants, Antithrombotic and Thrombolytic Agents.- A. Anticoagulants.- B. Thrombolytic Therapy.- C. Antithrombotic Therapy.- References.- 12 Granulocyte-Macrophage Growth Factors.- A. Introduction.- B. Historical Background.- C. Growth Factors.- D. Other Interleukins.- E. Inhibitors.- F. Cellular Production and Networking.- G. Microenvironment.- H. Conclusions.- References.- 13 Chemical Agents Which Suppress Myelopoiesis: Agranulocytosis and Leukemia.- A. Introduction.- B. Normal Marrow Cell Kinetics.- C. Pathophysiologic Mechanisms for Drug-Induced Neutropenia.- D. Neutropenia Associated with Cytotoxic Chemotherapeutic Agents.- E. Drug-Induced Myeloid Suppression.- F. Idiosyncratic Neutropenias.- G. Pseudoneutropenia.- H. Secondary Leukemia.- J. Conclusions.- References.- 14 Drugs Useful in the Chemotherapy of the Acute Leukemias.- A. Introduction.- B. Antimetabolites.- C. Drugs that Intercalate in DNA.- D. Podophyllotoxin Derivatives.- E. Vinca Alkaloids.- F. Alkylating/DNA Binding Agents.- G. Adrenal Glucocorticoids.- H. Enzymes.- J. Multidrug Resistance.- References.

最近チェックした商品